What does it mean for an antibody to take on multiple targets at once? 🎯 In this One Minute Thesis, watch one of our #scientists explain how #MultispecificAntibodies may help create new treatment approaches. [Video description: An AbbVie scientist in the lab explains how multispecific antibodies work. On-screen text reads, “One Minute Thesis, Multispecific Antibodies.”]
AbbVie
Fabricación de productos farmacéuticos
North Chicago, Illinois 1.672.089 seguidores
Sobre nosotros
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases. AbbVie employs approximately 26,000+ people worldwide and markets medicines in more than 170+ countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter and like us on Facebook.
- Sitio web
-
http://xmrrwallet.com/cmx.pwww.abbvie.com
Enlace externo para AbbVie
- Sector
- Fabricación de productos farmacéuticos
- Tamaño de la empresa
- Más de 10.001 empleados
- Sede
- North Chicago, Illinois
- Tipo
- Empresa pública
- Especialidades
- Biopharmaceutical, Biotechnology, Innovation, Research and Development, Manufacturing, Biotherapeutics, Oncology, Immunology, Virology, Neuroscience, Womens Health, Aesthetics y Eye Care
Ubicaciones
Empleados en AbbVie
Actualizaciones
-
That's a wrap on AbbVie In Motion, our annual 4-week virtual fitness challenge for employees. This year’s theme, "Get Outside for '25," encouraged employees to spend at least 25 minutes outside – walking, running, biking, hiking and more. More than 19,000 participants logged more than 29 million activity minutes – equal to running 550,000 marathons. AbbVie In Motion aims to help our employees be at their best by promoting health, well-being and connection. Thanks to all who participated and helped make this year's challenge a success. #AbbVieLife [Video description: On-screen text highlights key results from this year’s AbbVie In Motion along with images of employees participating in activities such as running, riding bikes, playing pickleball and more.]
-
NEWS: We recently announced a licensing agreement with Ichnos Glenmark Innovation (IGI) for a trispecific antibody currently in development for #MultipleMyeloma. This agreement reinforces our commitment to advance novel therapies, including multispecific antibodies for people living with #cancer. Learn more here: https://xmrrwallet.com/cmx.pbit.ly/44APaa0 [Video description: On-screen text reads, "Oncology News."]
-
#HidradenitisSuppurativa (HS) can be a debilitating chronic disease with physical and mental effects – 24% of people with HS have at least one mental health diagnosis. That’s why we’re focused on finding additional treatment options to help #patients find relief. https://xmrrwallet.com/cmx.pbit.ly/3Ty7LhX [Video description: A person shares their experience with hidradenitis suppurativa and an AbbVie scientific leader shares how we’re working to address patients’ needs.]
-
Join a team that fosters growth, innovation and endless learning, where greatness is achieved through collaboration. Start your journey with us today and see how far your #career can grow: https://xmrrwallet.com/cmx.pbit.ly/3ZWJu8U #AbbVieLife #Careers
-
-
JUST IN: We’ve signed a definitive agreement to acquire Capstan Therapeutics. This agreement underscores our commitment to drive scientific innovation and transform patient care in #immunology. Learn more: https://xmrrwallet.com/cmx.pbit.ly/4nta43y [Video description: On-screen text reads, "Immunology News."]
-
The AbbVie Foundation’s Week of Possibilities is currently underway. This global, week-long #volunteering program unites our employees around the world in service. 🌎 Thank you to the thousands of employees serving our communities this week and showing how #AbbVieGivesBack.
-
-
By addressing barriers to care in #ParkinsonsDisease (PD), we can create meaningful change for patients and their care partners. That’s why we’re working with global partners to encourage action. Learn more about our pledge to improve #healthcare services for these patients: https://xmrrwallet.com/cmx.pabbv.ie/4e80cb [Icon representing a world. On-screen text reads, “Parkinson’s disease (PD) is a progressive, neurodegenerative disorder affecting 1.2 million in Europe and 11.8 million people worldwide. Improvements in health care and accelerated action are crucial to enhance care in the PD community.”]
-
DYK #ParkinsonsDisease (PD) is one of the fastest-growing neurodegenerative disorders worldwide? At #EAN2025, we’re hosting a meeting with Parkinson's Europe and the European Federation of Neurological Associations on enhancing care in PD. Read how we’re encouraging action & working together to improve care for this community: https://xmrrwallet.com/cmx.pbit.ly/4lmF9Eh [Video description: Bjoern Fritz, Therapeutic Area Head, International Neuroscience, Eye Care & Specialty, International Medical Affairs, AbbVie, says, “As Parkinson's progresses, it can have a significant impact not only on the person but also on their family and care partners. We are aiming to transform the standards of care for patients and the Parkinson’s disease community.”]
-
Only a few days until #EAN2025. At the congress, we’ll be presenting new data on #migraine and #ParkinsonsDisease. If you’re attending, check out our presentations and learn how we’re helping move #science forward to make a difference in the #neuroscience community: https://xmrrwallet.com/cmx.pbit.ly/45u1RWn
-
Páginas asociadas
Páginas similares
Financiación
AbbVie
2 rondas en total
Ver más información en Crunchbase
Última ronda
Deuda tras OPV
Enlace externo a Crunchbase para la última ronda de financiación
15.000.000.000,00 US$